Ad Hoc Group Statement on NIH Funding in FY 2022 Omnibus

March 9, 2022 – The Ad Hoc Group for Medical Research issued the following statement in response to funding for the National Institutes of Health (NIH) included in the Consolidated Appropriations Act, 2022.

“Medical research turns the hope of improved health into a reality for patients and their families, and the fiscal year (FY) 2022 spending bill released today takes a step forward toward cures we have yet to discover. The Ad Hoc Group for Medical Research appreciates the $2.025 billion increase included in the FY 2022 omnibus for NIH’s base, which will support more research and more researchers striving for the next breakthrough treatments, diagnostics, and preventive interventions.

We are grateful for the leadership of House Appropriations Chair Rosa DeLauro (D-Conn.), Labor-HHS-Education Subcommittee Ranking Member Tom Cole (R-Okla.), Senate Appropriations Labor-HHS-Education Subcommittee Chair Patty Murray (D-Wash.), and Ranking Member Roy Blunt (R-Mo.), for driving a seventh consecutive year of bipartisan growth for the NIH within the confines of the overall discretionary spending limits.

Looking ahead, we must ensure that Congress continues to move forward in the nation’s commitment to medical research. At this time of unprecedented scientific opportunity, and to make progress toward the president’s — and all of our — goals of addressing the nation’s most burdensome and devastating diseases, sustained, robust growth in the foundational work the NIH supports will be essential to ensure we are not placing artificial bounds on our capacity for discovery.

We urge lawmakers to work quickly to pass the omnibus. If we are to fully realize the potential of medical discovery, we must ensure robust growth for the NIH in this fiscal year and beyond.”

*****

The Ad Hoc Group for Medical Research is a coalition of nearly 400 patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry. The Ad Hoc Group has one mission: to enhance the federal investment in biomedical, behavioral, social, and population-based research by increasing the funding for the National Institutes of Health.